Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 109 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Essential Hypertension Clear all
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension

NCT01523067
View directory record Official record
Conditions
Essential Hypertension
Interventions
Vasomera (PB1046), 0.9% Sodium Chloride
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
5
States / cities
Anniston, Alabama • Walnut Creek, California • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

NCT00846365
View directory record Official record
Conditions
Essential Hypertension
Interventions
Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil-hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,085 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
70
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hueytown, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Not applicable Interventional

Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome

NCT06461273
View directory record Official record
Conditions
Diabetes Mellitus, Metabolic Syndrome, Obesity, Hypertension,Essential, Hyperlipidemias, Cardiovascular Diseases, Kidney Disease, Chronic
Interventions
Lifestyle Medicine Program, Medically Tailored Groceries
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

NCT00739973
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule, Amlodipine 10 mg capsule, Aliskiren/amlodipine 150/5 mg tablet, Aliskiren/amlodipine 150/10 mg tablet, Aliskiren/amlodipine 300/5 mg tablet, Aliskiren/amlodipine 300/10 mg tablet
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 5, 2011 · Synced Jul 22, 2026, 5:00 AM EDT
Recruiting No phase listed Observational

Childhood-Onset Essential Hypertension Natural History Study

NCT06778239
View directory record Official record
Conditions
Hypertension, Essential Hypertension
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
2,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure

NCT00662610
View directory record Official record
Conditions
Osteoarthritis, Hypertension
Interventions
naproxcinod 375 mg -750 mg -1125 mg bid, naproxen 250 mg - 500mg -750 mg bid
Drug
Lead sponsor
NicOx
Industry
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
29
States / cities
Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

NCT00631917
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Placebo to Ramipril, Placebo to Aliskiren
Drug · Other
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Not applicable Interventional Results available

Implementing Hypertension Screening Guidelines in Primary Care

NCT03480217
View directory record Official record
Conditions
Hypertension,Essential, White Coat Hypertension
Interventions
Multifaceted Implementation Strategy, Usual care
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Jul 22, 2026, 5:00 AM EDT
Recruiting Not applicable Interventional

Mobile Health Program for Rural Hypertension

NCT05546931
View directory record Official record
Conditions
Hypertension,Essential, Adherence, Medication, Quality of Life
Interventions
Coaching application, WebMD, Home-based blood pressure monitoring
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

NCT00696384
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil, Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications., Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
33
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2012 · Synced Jul 22, 2026, 5:00 AM EDT
Completed No phase listed Observational

A Real-world Study of the Safety of Hypertension Medication Therapy in Japanese Patients With Naïve Hypertension

NCT06683768
View directory record Official record
Conditions
Hypertension
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40,563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

NCT02235909
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan Medoxomil Low-dose, Losartan, Placebo for Azilsartan Medoxomil, Placebo for Losartan, Azilsartan Medoxomil Medium-dose (20 mg), Azilsartan Medoxomil High-dose (40 mg)
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 18 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
17
States / cities
Anaheim, California • Hialeah, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

NCT00698646
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan + HCTZ, Valsartan, HCTZ
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
70 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Escondido, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Jul 22, 2026, 5:00 AM EDT
Terminated Not applicable Interventional

Motivational Interviewing

NCT00208104
View directory record Official record
Conditions
Essential Hypertension
Interventions
Motivational Interviewing
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2013 · Synced Jul 22, 2026, 5:00 AM EDT
Suspended Phase 3 Interventional

Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)

NCT07083765
View directory record Official record
Conditions
Hypertension, Hypertension,Essential
Interventions
Dehydrated Alcohol Injection, USP, Sham procedure
Drug · Procedure
Lead sponsor
Ablative Solutions, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.

NCT00250562
View directory record Official record
Conditions
Hypertension
Interventions
valsartan plus hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Jul 22, 2026, 5:00 AM EDT
Recruiting Not applicable Interventional

Dose-Response Effects of Inspiratory Muscle Strength Training on Blood Pressure and Vascular Function

NCT07109739
View directory record Official record
Conditions
Systolic Hypertension, Brachial Artery Flow-mediated Dilation
Interventions
POWERbreathe K5
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

NCT01281306
View directory record Official record
Conditions
Systolic Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Clearwater, Florida • Chicago, Illinois • Metairie, Louisiana + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 1 Interventional

Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension

NCT01873885
View directory record Official record
Conditions
Essential Hypertension
Interventions
Placebo Single IV (Intravenous) Infusion, Experimental: Single IV Infusion Vasomera (PB1046)
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Jul 22, 2026, 5:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Study Roles of Heavy Metals and Essential Metal Dyshomeostasis in Pulmonary Arterial Hypertension Patients

NCT04756076
View directory record Official record
Conditions
Pulmonary Hypertension, Metal Poison
Interventions
Metal level measurements
Diagnostic Test
Lead sponsor
Jiapeng Huang
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY2623091 in Participants With High Blood Pressure

NCT02194465
View directory record Official record
Conditions
Primary Hypertension
Interventions
LY2623091, Tadalafil, Spironolactone, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
33
States / cities
Glendale, Arizona • Concord, California • Encinitas, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 3 Interventional

Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension

NCT01415505
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Valsartan and Hydrochlorothiazide
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
135
States / cities
Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Jul 22, 2026, 5:00 AM EDT
Recruiting No phase listed Observational

Global Paradise System US Post Approval Study

NCT06297291
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions
Paradise Ultrasound Renal Denervation Treatment
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
39
States / cities
Sacramento, California • Santa Monica, California • Aurora, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 22, 2026, 5:00 AM EDT
Completed Phase 2 Interventional

A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension

NCT00779181
View directory record Official record
Conditions
Hypertension
Interventions
ADX415, Placebo
Drug
Lead sponsor
Addrenex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2008 · Synced Jul 22, 2026, 5:00 AM EDT